| 主权项 |
1. A method of identifying a risk for a bronchogenic carcinoma in an subject comprising:
obtaining a sample from the subject, determining transcript abundance (TA) in the sample for a biomarker signature found in the sample, wherein the TA is determined by microarray analysis, quantitative polymerase chain reaction, or a combination of both, and wherein the biomarker signature consists of:
i) at least one antioxidant gene selected from the group consisting of: CAT, GPX1, GPX3, GSTM3, GSTP1, GSTT1, GSTZ1, MGST1 and SOD1;ii) at least one DNA repair (DNAR) gene selected from the group consisting of: ERCC4, ERCC5 and XRCC1; andiii) transcription factor gene CEBPG, wherein the threshold levels for the genes comprise, where the second column is the cut-point determination on a log10 scale, and where CA =cancer risk:CATCA ≦ 4.81 or CA ≧ 5.18 GPX1CA ≦ 5.50 or CA ≧ 5.83GPX3CA ≦ 3.31 or CA ≧ 3.47GSTM3CA ≦ 3.20 or CA ≧ 3.55GSTP1CA ≦ 6.38 or CA ≧ 6.70GSTT1CA ≦ 3.49 or CA ≧ 3.88GSTZ1CA ≦ 3.18 or CA ≧ 3.68MGST1CA ≦ 4.93 or CA ≧ 5.20SOD1CA ≦ 5.09 or CA ≧ 5.41ERCC4CA ≦ 2.55 or CA ≧ 3.04ERCC5CA ≦ 4.81 or CA ≧ 5.11XRCC1CA ≦ 4.57CEBPGCA ≦ 4.09 or CA ≧ 4.44; and determining if said TA for each gene in the biomarker is within the threshold levels for each gene, wherein, when said TA for each gene is within said threshold levels, such determination indicates whether said subject is at greater risk for a bronchogenic carcinoma. |
